Literature DB >> 21352151

Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis.

José M Pelayo-Terán1, Rocío Pérez-Iglesias, Mariluz Ramírez-Bonilla, César González-Blanch, Obdulia Martínez-García, Gema Pardo-García, José M Rodríguez-Sánchez, Roberto Roiz-Santiáñez, Diana Tordesillas-Gutiérrez, Ignacio Mata, José Luis Vázquez-Barquero, Benedicto Crespo-Facorro.   

Abstract

AIM: The aim of the study was to analyse the treated incidence of schizophrenia in Cantabria (Northern Spain) and the sociodemographic risk factors associated with the illness onset.
METHODS: Data were obtained from patients included in the Cantabria's Clinical Programme on First-Episode Psychosis (schizophrenia spectrum DSM-IV diagnosis) from 2001 to 2005, from the Cantabria first-episode schizophrenia study (carried out between 1988 and 1989) and from the 2001 Spanish census.
RESULTS: Annual incidence was 1.38 per 10,000 inhabitants in the risk-ageperiod. Identified risk factors were male gender (relative risk (RR): 1.61), age 15-25 years (RR: 3.48), unemployment (RR: 2.82), single status (RR: 5.88), low educational level (RR: 4.38), urban environment (RR: 1.62) and cannabis consumption (odds ratio: 12.83). The incidence in females was significantly lower than the one obtained 15 years ago.
CONCLUSIONS: The reported factors suggest that underlying biological and social factors modulate the risk of psychosis. This balance operates differently in males and females.
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 21352151     DOI: 10.1111/j.1751-7893.2008.00074.x

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  28 in total

1.  Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.

Authors:  Benedicto Crespo-Facorro; Rocío Pérez-Iglesias; Ignacio Mata; Obdulia Martínez-Garcia; Victor Ortiz; Jose Maria Pelayo-Terán; Elsa Valdizan; José Luis Vazquez-Barquero
Journal:  Psychopharmacology (Berl)       Date:  2011-07-07       Impact factor: 4.530

2.  Homocysteine and cognition in first-episode psychosis patients.

Authors:  Rosa Ayesa-Arriola; Rocío Pérez-Iglesias; José Manuel Rodríguez-Sánchez; Ignacio Mata; Elsa Gómez-Ruiz; Maite García-Unzueta; Obdulia Martínez-García; Rafael Tabares-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-02       Impact factor: 5.270

3.  Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).

Authors:  José María Pelayo-Terán; Virginia Gajardo Gajardo Galán; Víctor de la Ortiz-García de la Foz; Obdulia Martínez-García; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro; Rosa Ayesa-Arriola
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-28       Impact factor: 5.270

4.  Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.

Authors:  Benedicto Crespo-Facorro; Victor Ortiz-Garcia de la Foz; Ignacio Mata; Rosa Ayesa-Arriola; Paula Suarez-Pinilla; Elsa M Valdizan; Obdulia Martinez-Garcia; Rocío Pérez-Iglesias
Journal:  Psychopharmacology (Berl)       Date:  2014-01       Impact factor: 4.530

5.  Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features.

Authors:  B Crespo-Facorro; R Roiz-Santiáñez; R Pérez-Iglesias; J M Rodriguez-Sanchez; I Mata; D Tordesillas-Gutierrez; E Sanchez; R Tabarés-Seisdedos; N Andreasen; V Magnotta; J L Vázquez-Barquero
Journal:  Psychol Med       Date:  2010-10-14       Impact factor: 7.723

6.  Disentangling early and late onset of psychosis in women: identifying new targets for treatment.

Authors:  Alexandre Díaz-Pons; Alexandre González-Rodríguez; Victor Ortiz-García de la Foz; Mary V Seeman; Benedicto Crespo-Facorro; Rosa Ayesa-Arriola
Journal:  Arch Womens Ment Health       Date:  2022-02-18       Impact factor: 3.633

7.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

8.  Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.

Authors:  Rosa Ayesa-Arriola; Jose Manuel Rodríguez-Sánchez; Rocío Pérez-Iglesias; Roberto Roiz-Santiáñez; Obdulia Martínez-García; Jose Sánchez-Moreno; Rafael Tabarés-Seisdedos; Jose L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

9.  Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.

Authors:  Javier Vázquez-Bourgon; Rocío Pérez-Iglesias; Víctor Ortiz-García de la Foz; Paula Suárez Pinilla; Álvaro Díaz Martínez; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-10-26       Impact factor: 4.530

10.  Diagnosis and neurocognitive profiles in first-episode non-affective psychosis patients.

Authors:  Rosa Ayesa-Arriola; José Manuel Rodríguez-Sánchez; Esther Setién Suero; Lauren E Reeves; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-01-14       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.